Claritas Announces Approval from OTC to Up-List to OTCQB
07 avr. 2022 07h30 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") is pleased to announce...
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
05 avr. 2022 07h15 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced that...
Claritas Announces Receipt of Comments from Australian Ethics Committee Regarding the Company’s Phase 1 Clinical Study of R-107 and Closing of Financing
22 févr. 2022 07h30 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...
Claritas Anticipates Response from Australian Ethics Committee by February 18, 2022
09 févr. 2022 07h15 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that the...
Claritas Announces Revised, Improved Terms for Initial Tranche of Financing with Alumina Partners
26 janv. 2022 17h50 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced revised, improved...
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns
17 janv. 2022 07h30 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") today announced that it has signed...
Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners
17 janv. 2022 07h00 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s new...
Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.
12 janv. 2022 13h23 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has...
Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries
04 janv. 2022 07h30 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s...
Claritas to Develop R-107 for Treatment of PPHN, a Potentially Fatal Pulmonary Disorder in Newborns
22 déc. 2021 07h15 HE
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it will...